On Demand: 2025-06-25: Don’t Skip a Beat… Cardiovascular Pharmacotherapy Update - Lake Placid
“Dr. Saseem is awesome. His knowledge of lipid lowering drug clinical trials is impressive and inspirational. You can always tell a good conference by the level of engagement between the class and speaker. The questions and discussion are the best I’ve ever experienced. There’s not a question he won’t take the time to answer. The only downfall is that all this learning uses more energy than fuel provided. A snack bar to help make it through that last lecture before lunch would fix that ; )
The course was very well organized. The topics and information was relevant and presented in a way that was easy to understand. The speaker was engaging, knowledgeable, and concise. I also liked the quizzes to help cement what we learned. I will definitely look to attend another program when I can.
This session on lipids was exactly what I needed!!! Thank you - very informative! I also really appreciate the discussion about the development of new drugs in trials and when they are supposed to be approved or not. Not many speakers give that information and it’s so good to know!!
Thank you for a wonderful presentation. Appreciated the in-depth overview on cholesterol, statins and management.
Incredible day of content, thank you so much! Dr. Sanseen is engaging and energetic. His knowledge and the way he delivers the information is exceptional!
Enjoyed the course and appreciated the expertise of the speakers.
Our course speaker relayed information very much on point and tried to answer questions from Zoom participants as well. The challenge in the course was in the problems with the participant questioning survey in which there were technical snafus during the program but that is not the fault of the speaker. It was overall helpful to have questions on survey for participant review of material.”
-
1. Explain recommendations from the American College of Cardiology/American Heart Association guidelines for treatment of patients with hypertension
2. Review lifestyle modifications that are recommended for the treatment and prevention of cardiovascular disease
3. Summarize how future cardiovascular risk is estimated in primary prevention patients using the Pooled Cohort Equations and PREVENT calculator
4. Formulate a care plan for patients with resistant hypertension based on the 2018 American Heart Association scientific statement
5. Describe emerging pharmacotherapies for the treatment of hypertension
6. List guideline recommendations supporting the use of antiplatelet therapy for primary prevention patients
7. Examine the evidence-based CV risk reduction benefits of medications used to treat overweight and obese patients
8. Create treatment plans that reduce the risk of cardiovascular disease
-
1. Explain recommendations from the American College of Cardiology/American Heart Association guidelines for treatment of patients with hypercholesterolemia, chronic coronary disease, and peripheral arterial disease
2. Apply the treatment approaches recommended in the 2018 ACC-AHA cholesterol guideline to patients with hypercholesterolemia
3. Interpret recommendations from the ACC Expert Consensus Decision Pathway for non-statins and treatment of hypertriglyceridemia
4. Define the evidence and role in therapy of nonstatin medications in the treatment of hypercholesterolemia
5. Describe the evidence and guideline recommendations supporting the use of antiplatelet and antithrombotic therapy for secondary prevention patients
6. List evidence-based drug therapy recommendations for the management of patients with chronic coronary disease and peripheral arterial disease
7. Evaluate the role of colchicine in the prevention of CV events
8. Create treatment plans that reduce the risk of cardiovascular disease
-
1. Explain recommendations from the American College of Cardiology/American Heart Association guidelines for treatment of patients with heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, and atrial fibrillation
2. Describe the pillars of therapy for heart failure
3. Examine results from cardiovascular outcome trials evaluating the use of angiotensin–neprilysin inhibition in heart failure with reduce ejection fraction
4. Examine results from cardiovascular outcome trials evaluating the use of SGLT2 inhibitors in heart failure
5. Discuss pharmacotherapy used for reducing the risk of stroke and rate and rhythm control in atrial fibrillation.
6. Recall strategies to promote health equity in cardiovascular disease management.
7. Create treatment plans that reduce the risk of cardiovascular disease
About This Course
This on demand course was recorded live in Lake Placid in June 25-26 2025. It provides 15 hours. live AAFP/ AMA PRA Category 1 Credit™, ACPE and pharmacology CE/ CME credit.
Price $299
Dr. Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS, BCACP
Joseph Saseen is Associate Dean for Clinical Affairs and Professor of Clinical Pharmacy and a Professor of Family Medicine. He also served as Vice Chair of the Department of Clinical Pharmacy for 10 years. Dr. Saseen has responsibilities for enhancing the school’s clinical enterprise, further developing sustainable clinical service models, and advocating for advancing the practice of pharmacy in the State of Colorado. His scholarly work includes almost 200 peer-reviewed publications and book chapters.
TARGET AUDIENCE/ ACCREDITATION
PHARMACISTS :University Learning Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. These programs are accredited for pharmacists.
NURSE PRACTITIONERS/ NURSES: This course provides 15 contact hours (1.5 CEU) over three days, 5 hours per day, to fulfill the pharmacotherapeutics/ pharmacology requirements for American Nurses Credentialing Center (ANCC) Category 1 Continuing Education Hours for certification renewal. The same hours submitted to renew certification may be submitted to a State Board of Nursing for re-licensure. American Nurses Credentialing Center (ANCC) accepts formally approved continuing education sponsored by organizations accredited or approved by the Accreditation Council for Pharmacy Education (ACPE). .
PHYSICIANS: The AAFP has reviewed Providing Better Patient Care June 10-12, 2025 and deemed it acceptable for up to 15.00 AAFP Prescribed credit(s). Term of Approval is from 06/10/2025 to 06/12/2028. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
CME programs approved by the AAFP are eligible for Category 2 credit (or Category 1-A under special circumstances) through the American Osteopathic Association (AOA).
PHYSICIAN ASSISTANTS: American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for Prescribed credit from AAFP. Physician assistants may report the number of hours stated above of Category I credit for completing this program.
CONSULTANT PHARMACISTS: Some consultant pharmacist boards accept University Learning Systems courses for recertification either as is or with board approval. Please contact your board regarding course approval and ULS with any questions.
CANADIAN PHARMACISTS: Canadian Council on Continuing Education in Pharmacy (CCCEP) accepts courses accredited by the Accreditation Council for Pharmacy Education (ACPE). This credit is applicable to health professionals who may require pharmacology credit.
CANADIAN PHYSICIANS: Members of the College of Family Physicians of Canada are eligible to receive up to 15 MAINPRO-M1 credits for participation in this activity due to reciprocal agreement with the American Academy of Family Physicians.
OTHER HEALTH PROFESSIONALS: Contact your respective board regarding approval.